<unk> , sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers.<unk>  is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. It is on the World Health Organization's List of Essential Medicines.
Ibrutinib
Bosutinib
Imatinib
Acalabrutinib
Ruxolitinib
Ponatinib
Afatinib
Zanubrutinib